Table 2.

Summary of significant SNP-disease interactions for invasive melanoma (M-inv; top panel) and basal cell carcinoma (BCC; bottom panel).

Chr	SNP	Allele	Odds Ratio	P-value (FDR)	Gene	Location
16	rs9926296	A	0.809446	3.77E-12	FANCA	intron 31
16	rs3743860	C	1.1965	1.29E-08	FANCA	intron 31
16	rs2376883	A	0.848934	1.92E-06	FANCA	intron 29
Chr	SNP	Allele	Odds Ratio	P-value (FDR)	Gene	Location
1	rs12046289	A	0.914388	0.000104	DCLRE1B	intron 2
1	rs4149909	G	1.12746	0.021555	EXO1	exon 7
6	rs61748588	A	1.18706	0.049773	GTF2H4	exon 5
8	rs28928581	C	1.08347	0.043767	RRM2B	intron 5
13	rs4942486	T	1.0483	0.011646	BRCA2	intron 21
14	rs4902628	C	0.958423	0.046463	RAD51B	intron 11
16	rs9926296	A	0.920691	2.42E-09	FANCA	intron 31
16	rs3743860	C	1.07056	5.88E-06	FANCA	intron 31
16	rs2376883	A	0.939527	0.000104	FANCA	intron 29
16	rs1800347	C	1.11993	0.004734	FANCA	intron 33
16	rs62989960	T	0.874634	0.004734	FANCA	intron 25

Odds ratios represent the probability of the tested minor allele of each SNP to be found in the disease versus healthy control group. Significance for each allele has been determined using the False Discovery Rate (FDR) method. Each SNP is annotated for its chromosomal position (Chr), the localizing gene, and its location (intron or exon) within the gene.